ADMA Biologics (ADMA) is a plasma-derived biologics manufacturer based in Ramsey, New Jersey, with its main production facility in Boca Raton, Florida. The company generated $510.2M of revenue and $191.4M of operating income in 2025, then reported flat revenue of $114.5M in the first quarter of 2026 while gross margin expanded to 70.5%. Cash stood at $138.2M at the end of the quarter, compared with $196.9M of debt and $222.1M of inventory. The business has become much more profitable, but management cut its 2026 revenue forecast by at least $75M only ten weeks after issuing it and withdrew all guidance beyond 2026.
The tension is straightforward. ASCENIV, ADMA’s differentiated immunoglobulin product, continues to grow and now accounts for most of the company’s revenue. BIVIGAM, its standard IVIG product, is losing ground in an increasingly aggressive market. ADMA’s value depends on whether ASCENIV can carry the business while manufacturing yields improve, working capital normalizes, and competition remains contained.
Research cutoff: August 4, 2026. ADMA had not filed its second-quarter 2026 Form 10-Q as of this date. The valuation below was prepared without reference to ADMA’s current share price or analyst estimates.
What ADMA Sells
ADMA manufactures therapies made from donated human plasma. Its three commercial products serve patients with immune deficiencies or specific infectious-disease risks.
| Product | Description | Role in the Business |
|---|---|---|
| ASCENIV | IVIG for primary humoral immunodeficiency, manufactured from plasma selected for elevated levels of certain pathogen-specific antibodies | Main growth and margin driver |
| BIVIGAM | Standard IVIG for patients age two and older with primary humoral immunodeficiency | Secondary product facing pricing pressure |
| Nabi-HB | Hyperimmune globulin used following certain exposures to hepatitis B | Established niche product |
ADMA sells these products through pharmaceutical wholesalers, specialty pharmacies, distributors, hospitals, infusion providers, and other treatment organizations. The end users are patients, but ADMA’s direct customers are concentrated distribution intermediaries.
The company also earns smaller amounts from plasma sales, laboratory testing, contract manufacturing, fill-finish services, and licensing. These activities support the manufacturing platform, but finished immunoglobulin products drive the valuation.
ASCENIV Has Become the Business
The portfolio changed quickly between 2023 and 2026.
| $M | 2023 | 2024 | 2025 | Q1 2026 |
|---|---|---|---|---|
| ASCENIV revenue | 92.6 | 239.6 | 362.5 | 97.5 |
| BIVIGAM revenue | 140.2 | 142.4 | 122.0 | 15.4 |
| Total company revenue | 258.2 | 426.5 | 510.2 | 114.5 |
| ASCENIV share of revenue | 36% | 56% | 71% | 85% |
ASCENIV revenue increased 28% in the first quarter of 2026 while BIVIGAM revenue fell 54%. Total revenue was flat because growth in the higher-margin product barely offset the decline in standard IVIG.
ASCENIV uses plasma selected through ADMA’s proprietary donor-screening process. Fewer than 10% of tested donor samples normally satisfy the company’s high-titer requirements. ADMA pools that plasma to produce immunoglobulin with standardized elevated levels of certain antibodies, including antibodies that neutralize respiratory syncytial virus.
The company positions ASCENIV as a later-line option for complex or refractory patients. It also has a product-specific J-code, which helps providers identify and bill for the product. FDA approval was expanded in May 2026 to include patients age two and older.
These features support a better price and margin than standard IVIG, although ADMA does not disclose product-level profitability. The evidence appears indirectly in the consolidated results: gross profit increased sharply in Q1 2026 even though total revenue did not grow.
BIVIGAM Has Become a Secondary Product
BIVIGAM competes in the broader standard-IVIG market against much larger companies, including CSL, Grifols, Takeda, Octapharma, and Kedrion/BPL.
Management attributed BIVIGAM’s Q1 2026 decline to aggressive competitor pricing, larger discounts and rebates, extended payment terms, and changes in distributor inventory. The company chose not to match every competitive offer.
That may protect margins, but it changes BIVIGAM’s role. The product still provides revenue and helps utilize ADMA’s manufacturing facility. The filings no longer support treating it as a dependable growth engine.
The valuation therefore rests primarily on ASCENIV.
How ADMA Makes Money
The operating chain begins months before a product is sold:
- ADMA obtains normal and high-titer human plasma from company-owned and third-party collection centers.
- Donated plasma is tested, screened, and pooled.
- The plasma is fractionated at ADMA’s FDA-licensed Boca Raton facility.
- Immunoglobulin is purified, formulated, filled, tested, and released.
- Finished product is sold through distributors, wholesalers, and specialty pharmacies.
- Hospitals, clinics, infusion centers, and home-infusion providers administer the product.
- Public and private insurers reimburse providers, subject to coverage rules, rebates, and discounts.
The process takes seven to twelve months from plasma collection through FDA release. ADMA must pay for plasma, labor, testing, and inventory long before it collects cash from customers.
This creates three important economic levers.
Product Mix
Every dollar shifted from lower-margin BIVIGAM to higher-margin ASCENIV can increase gross profit without increasing total revenue.
Q1 2026 provided a clear example. Revenue was flat, but gross profit increased by $19.7M because ASCENIV represented a much larger share of sales.
Manufacturing Yield
ADMA received FDA approval for a manufacturing process that produces at least 20% more immunoglobulin from the same starting plasma volume.
Plasma is one of the company’s largest costs and one of its main supply constraints. A 20% yield improvement affects more than unit cost. It also increases the revenue that can be generated from existing plasma contracts and manufacturing infrastructure.
The first yield-enhanced commercial lots received FDA release during the third quarter of 2025. The financial benefit began appearing late in 2025 and became more visible in Q1 2026.
Facility Utilization
ADMA’s Boca Raton facility can process up to 600,000 liters of plasma annually. Much of the facility cost is fixed, including specialized labor, quality systems, validation, maintenance, and regulatory compliance.
Higher production spreads those costs across more finished product. This operating leverage drove much of the margin expansion between 2021 and 2025.
Capacity is not unlimited. The company has acquired additional property near the Boca Raton facility and continues to invest in automation, fill-finish capabilities, and supply-chain infrastructure. Capital expenditures are expected to remain higher than the levels reported before 2025.
The Margin Expansion Is Real
ADMA spent years funding a manufacturing ramp before the income statement improved.
| $M except margins | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 80.9 | 154.1 | 258.2 | 426.5 | 510.2 |
| Gross margin | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% |
| Operating income | (58.4) | (39.4) | 21.6 | 139.0 | 191.4 |
| Operating cash flow | (112.4) | (59.5) | 8.8 | 118.7 | 50.4 |
| Capital expenditures | 13.5 | 13.9 | 4.8 | 8.2 | 22.6 |
| Reported free cash flow | (125.9) | (73.4) | 4.0 | 110.5 | 27.8 |
Revenue grew at a 58% annual rate from 2021 through 2025. Gross margin improved from 1.4% to 57.4%, which converted a $58.4M operating loss into $191.4M of operating income.
Several factors produced that change:
- the Boca Raton facility moved from underutilization toward commercial scale;
- larger production batches spread fixed costs across more units;
- ASCENIV became a larger share of revenue;
- manufacturing yield improved;
- the company brought more fill-finish activity in-house;
- ADMA reduced reliance on unprofitable company-owned plasma centers.
The reported history still needs several adjustments.
In 2024, revenue and gross profit included a $12.6M release of a Medicaid rebate accrual. The same year included an $84.3M deferred-tax benefit, which made net income a poor measure of recurring earnings.
In 2025, revenue included a $4.0M reduction related to withdrawn BIVIGAM lots, along with replacement and related costs. Stock-based compensation also increased from $6.2M in 2023 to $20.0M in 2025.
ADMA’s underlying margin expansion remains substantial after these adjustments. The accounting items affect the exact level, not the direction.
Q1 2026 Exposed Both Strength and Weakness
The first quarter showed how profitable ADMA can be with a favorable product mix. It also showed how quickly standard-IVIG competition can disrupt total revenue.
| $M except margins | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 114.5 | 114.8 | Flat |
| ASCENIV revenue | 97.5 | 76.3 | +28% |
| BIVIGAM revenue | 15.4 | 33.5 | -54% |
| Gross profit | 80.8 | 61.1 | +32% |
| Gross margin | 70.5% | 53.2% | +17.3 pts |
| Reported operating income | 58.3 | 34.9 | +67% |
| Plasma-center sale gain | 8.0 | 0.0 | N/A |
| Normalized operating income | 50.3 | 34.9 | +44% |
| Normalized operating margin | 43.9% | 30.4% | +13.5 pts |
| Operating cash flow | 58.2 | (19.7) | +77.9 |
Reported operating income included an $8.0M gain from selling three plasma centers. Excluding that gain, operating margin was still 43.9%.
The 70.5% gross margin deserves some context. Q3 2025’s reported gross margin was 56.3%, but that quarter included a $13.8M spot-market plasma sale at a negative margin. Management reported a 63.7% product-level gross margin excluding the plasma transaction.
Q1 2026 benefited from:
- a higher ASCENIV mix;
- yield-enhanced production;
- no comparable negative-margin plasma sale;
- lower exposure to BIVIGAM;
- reduced losses from company-owned plasma centers.
A gross margin in the high 60% range may be achievable if ASCENIV keeps growing. Treating 70.5% as a permanent floor would be aggressive.
The Guidance Reset Changes the Underwriting
On February 25, 2026, management reiterated an ambitious growth plan.
By May 6, ten weeks later, the company had cut its outlook and withdrawn every forecast beyond 2026.
| 2026 guidance | February 2026 | May 2026 |
|---|---|---|
| Revenue | More than $635M | $530M to $560M |
| Adjusted EBITDA | More than $360M | $265M to $300M |
| Adjusted net income | More than $255M | $170M to $200M |
| 2027 to 2029 guidance | Reiterated | Withdrawn |
Using the midpoint of the May ranges:
- revenue guidance fell by at least $90M, or 14%;
- adjusted EBITDA guidance fell by at least $77.5M, or 22%;
- adjusted net income guidance fell by at least $70M, or 27%.
Management blamed sustained standard-IVIG pricing pressure and distributor inventory behavior. It maintained that ASCENIV demand remained strong, citing record patient starts, growing prescriber breadth, and 28% revenue growth.
ASCENIV’s reported growth supports part of that explanation. The size and speed of the guidance cut still matter.
ADMA generated $114.5M of revenue in Q1. Reaching the revised full-year guidance requires the following average quarterly revenue over the remaining nine months:
| 2026 Revenue Target | Revenue Needed After Q1 | Required Q2 to Q4 Average |
|---|---|---|
| $530M | $415.5M | $138.5M |
| $545M midpoint | $430.5M | $143.5M |
| $560M | $445.5M | $148.5M |
The low end requires average quarterly revenue 21% above Q1. The high end requires a 30% increase.
Management described Q1 as a trough. The remaining 2026 filings will determine whether that description was accurate.
Cash Conversion Is the Hard Part
ADMA’s income statement improved faster than its cash flow because the production cycle ties up money in receivables and inventory.
| $M | 2023 | 2024 | 2025 | TTM Through Q1 2026 |
|---|---|---|---|---|
| Operating cash flow | 8.8 | 118.7 | 50.4 | 128.3 |
| Capital expenditures | 4.8 | 8.2 | 22.6 | 20.4 |
| Reported free cash flow | 4.0 | 110.5 | 27.8 | 107.9 |
The trailing figure looks strong, but timing helped it.
During 2025:
- accounts receivable increased by $108.4M;
- inventory increased by $36.2M.
During Q1 2026:
- receivables declined by $22.6M, which increased cash flow;
- inventory increased by $15.6M, which reduced cash flow.
The March 31 balance sheet shows how much capital the operating cycle requires.
| $M | March 31, 2026 |
|---|---|
| Accounts receivable | 135.9 |
| Raw-material inventory | 89.3 |
| Work-in-process inventory | 67.5 |
| Finished-goods inventory | 65.3 |
| Total inventory | 222.1 |
Inventory equaled 44% of 2025 revenue. That investment is necessary because plasma must move through a long production, testing, and release process before ADMA can sell it.
Receivables also deserve close attention. Distributor concentration, extended payment terms in the IVIG market, and quarter-to-quarter ordering patterns can create large movements in both revenue and cash collection.
My valuation deducts incremental working-capital investment rather than treating recent reported free cash flow as immediately distributable.
The Moat Is a Regulated Manufacturing System
ADMA’s competitive protection comes from several connected assets.
| Asset | Why It Matters | Limitation |
|---|---|---|
| FDA-licensed Boca Raton facility | Expensive and time-consuming for a competitor to reproduce | Creates single-site manufacturing risk |
| Proprietary high-titer plasma screening | Helps create a differentiated immunoglobulin product | Depends on access to uncommon donor plasma |
| ASCENIV patents and trade secrets | Protect product composition, screening, pooling, and manufacturing methods | Filings do not disclose one clear expiration date for the entire franchise |
| Product-specific J-code | Supports provider billing and reimbursement | Does not prevent payer pressure or formulary restrictions |
| Long-term plasma contracts | Improve raw-material visibility | Include scheduled price increases and supplier dependence |
| Specialized commercial organization | Builds relationships with immunologists, pharmacies, and infusion providers | Larger competitors have broader portfolios and more resources |
The Grifols agreement requires at least 35,000 liters of RSV high-titer plasma per year and runs through September 2039.
The KEDPlasma agreement provides at least 35,000 liters annually and runs through July 2031. Together, these contracts give ADMA access to at least 70,000 liters of high-titer plasma per year once both are fully active.
The agreements reduce supply risk but do not eliminate it. ADMA depends on two large suppliers, and contract prices increase over time.
The patents also deserve a measured interpretation. ADMA lists multiple patents covering ASCENIV and related processes, but the 10-K does not provide one consolidated expiration date that protects every important element. Process knowledge, FDA approvals, plasma access, and manufacturing execution may provide more durable protection than any single patent.
Concentration Keeps the Risk High
ADMA is profitable, but the business remains concentrated.
Customer Concentration
Two customers generated 73% of 2025 revenue. Those customers represented 87% of accounts receivable at year-end.
Three customers generated 82% of Q1 2026 revenue. Two customers represented 82% of quarter-end receivables.
These customers are distribution channels rather than the ultimate patients. Losing one would not necessarily eliminate all underlying demand, but replacing a major distributor could disrupt ordering, inventory, payment timing, and revenue recognition.
Product Concentration
ASCENIV generated 85% of Q1 2026 revenue. That concentration supports margins while demand is growing. It also means a reimbursement change, safety issue, manufacturing interruption, or competitive product could affect most of the business.
Manufacturing Concentration
The Boca Raton facility sits at the center of ADMA’s production system. A significant FDA observation, contamination event, equipment failure, hurricane, or quality-control problem could interrupt both production and product release.
Because the manufacturing cycle takes up to twelve months, some consequences may appear long after the original problem.
Supplier Concentration
High-titer plasma is scarce. ADMA has long-term contracts with Grifols and KEDPlasma, but those agreements also make the company dependent on two major suppliers.
The company retains seven plasma centers after selling three locations. The hybrid model should reduce capital requirements and operating losses, but it also transfers more control to outside suppliers.
Management, Governance, and Capital Allocation
ADMA financed its manufacturing ramp with equity and expensive debt.
Year-end shares increased from 195.8M in 2021 to 237.9M in 2025. Existing shareholders paid for much of the infrastructure that now produces the company’s profits.
Management shifted toward repurchases after the business began generating cash. In March 2026, ADMA borrowed $125M under its revolving credit facility to fund an accelerated share repurchase.
| Balance Sheet Item | March 31, 2026 |
|---|---|
| Cash | $138.2M |
| Debt carrying value | $196.9M |
| Net debt | $58.7M |
| Shares outstanding at May 1 | 231.8M |
| Q1 diluted weighted-average shares | 240.0M |
The repurchase reduced outstanding shares, but it also converted a stronger cash position into modest net debt. The revolver carried a variable rate of 6.17% at quarter-end and matures in 2028.
Borrowing to repurchase shares can create value when the repurchase price is below intrinsic value. It also reduces flexibility if earnings disappoint or working capital consumes more cash than expected.
Stock Compensation Is a Real Cost
Stock-based compensation increased to $20.0M in 2025 and reached $6.3M in Q1 2026.
At March 31, the company had:
- 5.2M stock options outstanding;
- 4.7M restricted stock units outstanding;
- $66.2M of unrecognized stock-compensation expense.
Management’s adjusted EBITDA adds stock compensation back. My valuation leaves it in operating expenses and uses 240M diluted shares.
The repurchase deserves credit for reducing the basic share count. It does not make outstanding options, restricted units, or future grants disappear.
The Audit Committee Review
ADMA disclosed in May 2026 that its Audit Committee investigated allegations of illicit channel stuffing and undisclosed related-party transactions. The committee used independent forensic accountants and outside legal counsel.
According to the company, the investigation found:
- no improper channel stuffing;
- no undisclosed related-party transactions;
- no evidence of illegal activity;
- no need to adjust or restate the 2025 financial statements.
I have not applied a direct valuation penalty for an investigation that found no misconduct and produced no restatement.
The allegations were still aimed at areas that already require attention. ADMA has concentrated distributors, large receivables, and variable ordering patterns. Each quarterly filing should be checked for receivable growth, payment timing, customer inventory, and revenue concentration.
SG-001 Is Worth Zero in This Valuation
SG-001 is ADMA’s experimental hyperimmune globulin program targeting pneumococcal infections.
Management has described a potential annual market opportunity of $300M to $500M. That estimate is not enough to support an asset value. The program remains early, and development, regulatory, manufacturing, and commercial risks are substantial.
My valuation assigns no value to SG-001.
A successful program would add upside. A failed program would not reduce the estimated value of the existing commercial business, other than the cash spent developing it.
The pediatric ASCENIV label expansion is included in the core ASCENIV growth assumptions rather than valued as a separate pipeline asset.
Valuation
This section estimates ADMA’s intrinsic value without checking its current market price. It does not make a claim about upside or downside relative to the market.
I use two methods:
- a five-year discounted cash-flow model;
- a normalized 2026 earnings cross-check.
The DCF values the operating business using FCFF. Interest expense is excluded from operating cash flow, and net debt is deducted after calculating enterprise value.
Core Assumptions
All three scenarios use:
- a 21% tax rate;
- depreciation and amortization equal to 1.7% of revenue;
- $58.7M of net debt;
- 240M diluted shares;
- stock compensation included in operating expenses;
- no value for SG-001;
- no value for other unapproved products.
| Assumption | Bear | Base | Bull |
|---|---|---|---|
| 2026 revenue | $530M | $545M | $560M |
| 2030 revenue | $635M | $900M | $1.15B |
| 2025 to 2030 revenue CAGR | 4.5% | 12.0% | 17.7% |
| 2026 EBIT margin | 37% | 40% | 43% |
| 2030 EBIT margin | 33% | 44% | 51% |
| 2026 capital expenditures as % of revenue | 4.7% | 4.5% | 4.3% |
| 2030 capital expenditures as % of revenue | 2.8% | 2.5% | 2.4% |
| Incremental working capital as % of revenue growth | 40% | 35% | 32% |
| WACC | 11.5% | 10.5% | 9.5% |
| Terminal growth | 2.0% | 2.5% | 3.0% |
The bear case assumes BIVIGAM remains under pressure and ASCENIV growth slows. Revenue increases modestly, but operating margin declines as product pricing, plasma costs, and corporate expenses absorb the benefits of yield enhancement.
The base case assumes ASCENIV resumes steady growth after the 2026 disruption. Revenue reaches $900M in 2030, one year later and $200M below management’s withdrawn 2029 target. EBIT margin peaks at 45% before settling at 44%.
The bull case assumes ASCENIV maintains strong growth, yield enhancement produces durable savings, and the existing manufacturing platform supports more than $1B of annual revenue. It approaches management’s withdrawn long-term revenue target, but one year later.
Base-Case Cash Flow
| $M | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | 545.0 | 640.0 | 735.0 | 825.0 | 900.0 |
| EBIT margin | 40% | 43% | 45% | 45% | 44% |
| EBIT | 218.0 | 275.2 | 330.8 | 371.3 | 396.0 |
| FCFF | 144.8 | 172.6 | 218.5 | 253.5 | 279.4 |
The model does not use management’s adjusted EBITDA. It taxes operating income, adds depreciation and amortization, deducts capital expenditures, and deducts incremental working capital.
The 2026 capital-spending assumption is $24.5M, within management’s expected range of $22M to $27M.
DCF Results
| Scenario | Enterprise Value | Equity Value | Value Per Diluted Share | Terminal Value as % of EV |
|---|---|---|---|---|
| Bear | $1.45B | $1.39B | $5.79 | 65% |
| Base | $2.95B | $2.89B | $12.03 | 74% |
| Bull | $5.12B | $5.06B | $21.10 | 80% |
The dependence on terminal value increases with the growth assumptions. The bull case deserves the least confidence because 80% of enterprise value comes from cash flows beyond the explicit forecast period.
Base-Case DCF Sensitivity
| WACC | 2.0% Terminal Growth | 2.5% Terminal Growth | 3.0% Terminal Growth |
|---|---|---|---|
| 9.5% | $13.13 | $13.90 | $14.79 |
| 10.5% | $11.46 | $12.03 | $12.68 |
| 11.5% | $10.14 | $10.58 | $11.08 |
The base operating forecast produces a value between $10.14 and $14.79 under this range of discount rates and terminal-growth assumptions.
Normalized Earnings Cross-Check
For the earnings cross-check, I start with each scenario’s 2026 EBIT, deduct $12.3M of estimated annual interest expense, and apply a 21% tax rate.
| Scenario | Normalized 2026 Net Income | Earnings Multiple | Implied Value Per Share |
|---|---|---|---|
| Bear | $145M | 15x | $9.10 |
| Base | $163M | 20x | $13.50 |
| Bull | $181M | 25x | $18.80 |
These are not peer-comparison multiples.
The bear multiple reflects low growth, product concentration, falling margins, and execution risk. The base multiple assumes durable ASCENIV growth and strong returns on the existing manufacturing platform. The bull multiple requires sustained double-digit growth and confidence that current competitive advantages will remain intact.
Valuation Conclusion
| Scenario | DCF | Earnings Method | Valuation Range |
|---|---|---|---|
| Bear | $5.79 | $9.10 | $6 to $9 |
| Base | $12.03 | $13.50 | $12 to $14 |
| Bull | $21.10 | $18.80 | $19 to $21 |
My central estimate is $13 per diluted share, with a wider plausible range of $6 to $21.
The wide range reflects uncertainty around three variables:
- how quickly revenue recovers from the Q1 2026 disruption;
- whether ASCENIV can continue growing without material pricing pressure;
- whether operating margins remain near current levels after competition, plasma inflation, and corporate spending.
ASCENIV’s margin improvement is supported by actual results. The durability of its revenue growth has less evidence following the guidance reset.
What Could Make This Valuation Wrong
The bear case becomes more likely if:
- Q1 2026 was the start of a longer slowdown rather than a trough;
- standard-IVIG pricing pressure spreads to ASCENIV;
- distributors continue reducing inventory or demand longer payment terms;
- payer access or reimbursement becomes less favorable;
- plasma costs increase faster than ASCENIV pricing;
- a manufacturing or FDA issue interrupts the Boca Raton facility;
- working capital consumes more cash than the model assumes;
- management continues borrowing to repurchase shares during volatile operating periods.
The bull case becomes more likely if:
- ASCENIV sustains revenue growth above 20%;
- the pediatric label expansion adds meaningful patient volume;
- payer coverage and prescriber adoption continue expanding;
- yield-enhanced production keeps gross margin near 70%;
- ADMA generates more revenue from the existing facility without major expansion spending;
- BIVIGAM pricing stabilizes;
- working-capital efficiency improves after the plasma-center sale;
- SG-001 advances without requiring heavy outside financing.
The next several quarters should narrow the range. ADMA does not need to return immediately to its withdrawn 2029 targets to justify the base valuation. It does need to show that ASCENIV demand converts into revenue, cash collection, and sustainable free cash flow.
If you found this helpful, consider supporting my work. This blog has no paywalled content and reader support is how it stays that way. You can also subscribe to my mailing list to get new deep dives in your inbox.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Q2 2026 financial results | First direct test of management’s claim that Q1 represented a revenue trough | Expected August 2026 |
| Quarterly revenue above $138.5M | Required average to reach the low end of 2026 guidance after Q1 | Q2 through Q4 2026 |
| ASCENIV revenue growth | Determines whether the differentiated product can carry the portfolio | Each quarter |
| BIVIGAM pricing and volume | Shows whether standard-IVIG pressure is stabilizing or worsening | Each quarter |
| Gross margin after yield enhancement | Tests whether the Q1 margin increase is sustainable | Through 2026 |
| Accounts receivable | Large increases could signal slower collections, extended terms, or distributor inventory issues | Each quarter |
| Inventory growth | Indicates how much cash is required to support future production and sales | Each quarter |
| Debt repayment after the accelerated repurchase | Shows whether operating cash flow is rebuilding balance-sheet flexibility | 2026 and 2027 |
| Final accelerated-repurchase settlement | Determines the full reduction in diluted shares | 2026 |
| SG-001 pre-IND work | Could create pipeline value, although none is included in the current valuation | 2026 |
| Capital expenditures | Reveals whether the current facility can support growth without a major expansion cycle | 2026 and 2027 |
Sources:
- 2025 Form 10-K filed February 25, 2026
- 2023 Form 10-K filed February 28, 2024
- Q1 2026 Form 10-Q filed May 6, 2026
- Q3 2025 earnings release furnished November 5, 2025
- Full-year 2025 earnings release furnished February 25, 2026
- Q1 2026 earnings release furnished May 6, 2026
- ASCENIV pediatric label expansion Form 8-K filed May 4, 2026
- 2026 proxy statement filed April 15, 2026
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.